The U.S. Congress will approve money to fund psychedelic research for veterans — likely by tucking it into a must-pass military spending bill (the National Defense Authorization Act, or NDAA) or a Veterans Administration budget bill by mid-December 2026. This matters because Congress has already done this twice (in 2022 and 2023), showing veteran psychedelic research has real legislative support. Money means trials start, evidence accumulates, and veterans get earlier access to potential treatments.
Congress has repeatedly used the NDAA as a vehicle for veteran-focused psychedelic research provisions (e.g., 2022 and 2023 NDAA included psychedelic research funding language). Must-pass status of NDAA makes it the realistic path for niche medical policy. Veteran advocacy coalitions are organized and have established relationships with Armed Services Committee staff. Standalone psychedelic legislation faces near-zero floor time probability. Falsifiable: bill text searchable in Congress.gov. Confidence moderated because 'provisions' must be specific and survive conference — not merely introduced.